We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ceftriaxone Monotherapy in the Treatment of Low-Risk Febrile Neutropenia.
- Authors
Karthaus, M.; Wolf, H.H.; Kämpfe, D.; Egerer, G.; Ritter, J.; Peters, G.; Südhoff, T.; Franke, A.; Heil, G.; Kullmann, K.H.; Jürgens, H.
- Abstract
Febrile neutropenia in patients who have undergone chemotherapy is usually treated with a combination of broad-spectrum antibiotics. There are no exactly defined protocols for single-agent treatment because a clear definition of low risk febrile neutropenia is lacking. This paper examines the safety and efficacy of once-daily ceftriaxone in 376 cases. Material and Methods: In a prospective observational study carried out between February 1992 and January 1996, 959 febrile episodes at 48 hospitals were recorded. Inclusion criteria were neutropenia (absolute neutrophil count, ANC <1,000/µl) with fever (≥38.5°C) or a C-reactive protein concentration >1 mg/dl and suspected infection. Nine hundred and one episodes (acute leukemia n = 396, lymphoma n = 220, solid tumors n = 272 and other disorders n = 13) in 828 patients aged between 1 and 97 years were analyzed, of which 876 episodes were evaluable for response. All patients initially underwent empirical treatment with ceftriaxone (adults: 2 g/day; children: 80 mg/kg/day), either alone (376) or in combination with other agents (525). Results: The mean ANC was 423/µl (SD ± 316) and the median duration of neutropenia 10 days. Of the 363 episodes treated initially with ceftriaxone alone, 70.8% responded versus 56.9% in the combination therapy group. The favorable response to the initial monotherapy treatment was explained by a low-risk population in the monotherapy group. A KI >6 (p < 0.0001), ANC ≥500/µl (p = 0.0001) and a duration of ANC <5 days (p < 0.05) were significantly more frequent in the monotherapy arm and were predictive of lower risk at the commencement of treatment. Conclusion: Ceftriaxone is effective in febrile neutropenia. Treatment with ceftriaxone alone was safe and highly effective in low-risk patients. Single-agent regimens appear to be a suitable treatment option in low-risk febrile neutropenia.
- Publication
Chemotherapy (0009-3157), 1998, Vol 44, Issue 5, p343
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000007134